Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years ... for a slew of additional indications such ...

The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy ... This year’s 19th Annual New York Lung Cancers Symposium® will focus on treatment strategies in early-stage lung ...

"Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...